Sapient Featured in Biocompare Article, “Mass Spectrometry for Biomarker Discovery”
Biocompare recently spoke to a panel of experts, including Sapient’s CEO and Founder, Dr. Mo Jain, to get their takes on the challenges and opportunities of using mass spectrometry for biomarker discovery and research.
Dr. Jain shares his perspectives on how technological advances in mass spectrometry are “releasing the brakes” that have constrained analytical speed to finally enable large-scale, nontargeted #biomarker discovery. He also discusses the importance of performing both technical and biological validation of key biomarkers that are identified to help ensure they are the most biologically relevant measures for their context of use.
Click here to read the full article on Biocompare.